What is vepotuzumab (POLIVY)?

Vepotuzumab (POLIVY) is an anti-CD79b antibody-drug conjugate (ADC) currently approved for use in combination with bendamustine and rituximab in multiple countries, including the EU and the United States. In the United States, velpotuzumabin combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory disease who have received at least two prior therapies, and in Europe for the treatment of adult patients with relapsed or refractory diffuse largeB-cell lymphoma who are not suitable for hematopoietic stem cell transplantation.

Vepotolizumabis an anticancer drug that causes malignantB cell apoptosis. In vitro, it exerts a cytotoxic effect on most diffuse large B-cell lymphoma (DLBCL) cell lines, an effect that is consistent across all cell lines, regardless of the cell subtype of origin and whether they contain CD79B gene mutations. In a mouse xenograft model, velpotuzumab induced apoptosis and reduced proliferation of mature CD79b+ B cell NHL cell lines. Vepotuzumab can cause immunosuppression, including neutropenia and thrombocytopenia.

Vepotolizumab's patent medicine has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. It is an injectable preparation. The price of 30 mg per box may be around RMB 10,000. The price of the Hong Kong version of 140 mg per box may be around RMB 60,000 (the price may fluctuate due to exchange rates) overseas. The price of the European version of vepotuzumab on the market, Specifications140 mg per box, may be around 90,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs are basically the same as those of foreign original drugs, and they are expensive. There are currently no generic versions of vepotuzumab on the market.